clinical trial · NCT04396574
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company·phase3·terminated·n = 566
MigraineLasmiditan
brief summary
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
started
Jun 30, 2020
primary completion
Dec 4, 2025
completion
Dec 4, 2025
last updated
Mar 10, 2026
official title
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol